Industry News

Pfizer Inc announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults experience at least one major depressive episode in any given year."/>
Pfizer Launches New “Moodivator” App to Help Support, Encourage and Motivate People with Depression
Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that preclinical data from the Company’ s NeuVax™ program is being presented today at the Progress in Vaccination Against Cancer Conference in Winchester, UK. NeuVax contains the immunodominant peptide derived from the extracellular region of the..."/>
Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has closed its previously announced offering of common shares of the Company. The Offering was co-led by Cormark Securities Inc. and Canaccord Genuity Corp., and consisted of 9,146,400 Shares sold at a price of C $0.30 per Share,..."/>
Aequus Closes Financing for Gross Proceeds of C$2,743,920
Willis Towers Watson and Connecture, Inc. to give cities more health care options to offer to their employees and retirees through the League of California Cities’ Health Benefits Marketplace SM. The HMB launched in August and is a consumer-driven platform that lets cities redesign their approach to medical insurance and gives retirees and active employees coverage choices that..."/>
League of California Cities Announces New Partners in Offering Improved Health Benefits Options to Local Cities
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that is has been named as one of the winners of the..."/>
ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award
Vitality Biopharma, Inc., a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a recent article written by Robert Brooke, Company CEO, sheds new light on key factors in the fight against the increasing epidemic of prescription painkiller related deaths. Brooke notes, "Opiates are one of..."/>
Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications
Digipath, Inc., an independent cannabis lab testing and media firm, is pleased to announce that it will be a presenting company on the upcoming Cannabis Investor Webcast. The Webcast is scheduled to take place on Thursday, September 15, and Digipath is scheduled to present from 11 am ET to 11:45am ET. You can register for this Webcast by visiting and clicking the "Attend" button towards the top of the page."/>
Digipath to Present on Cannabis Investor Webcast on September 15, 2016
Kiwa Bio-Tech Products Group Corporation. On September 7, 2016, Kiwa Bio-Tech Products Group Corporation executed an agreement to acquire a seventy percent interest in Tangshan Deruifeng Technology Co., Ltd. for approximately 14,000,000 RMB to be paid 50% in cash and 50% in Kiwa common stock priced at eighty percent of the market price of the Company's stock on the effective date of the agreement. Founded in Jan, 2010 and located in Tangshan City, Hebei..."/>
Kiwa Announces Acquisition of 70% of Tangshan Deruifeng Technology Co., Ltd. for US$2,000,000
Zynex, an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring, announces today August 2016 electrotherapy orders. During the month of August, Zynex received 2,043 orders from clinics and patients for electrotherapy units. This is a 99% increase in orders compared to 1,028..."/>
Zynex Announces August Orders
Carlisle Companies Incorporated announced today that Jonathan Collins, Vice President and Head of eCommerce for Mylan N.V., has been elected to its Board of Directors, effective immediately. Mylan N.V. is a leading global pharmaceutical company, offering products to customers in 145 countries. Mylan’ s global headquarters are located in Canonsburg, PA, with 2015 net sales of $9.4 billion."/>
Carlisle Companies Elects Jonathan Collins to Board of Directors
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus infections. A safety committee reviewed the trial data and concluded AB-SA01 was well-tolerated by subjects in the trial..."/>
AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States
Premier Farnell by a US rival has been backed by shareholders. Premier Farnell will be the second UK tech star to fall into foreign hands this summer, after Cambridge-based ARM Holdings was snapped up by Japan's SoftBank for pounds sterling 24 bn. American IT giant Avnet has agreed to pay 185 p per share for the Leeds-based firm after trumping an earlier offer of 165 p per share from Swiss firm Datwyler."/>
Daily Mail, London, business briefs column [Daily Mail, London]
Associated British Foods was the surprise biggest faller."/>
Daily Mail, London, market report column [Daily Mail, London]
Connecture, a provider of web-based information systems used to create health insurance marketplaces. Amendola will effectively serve as the company's public relations arm, leveraging its many relationships with industry media..."/>
Connecture Selects Amendola Communications as New PR Agency
Critical Outcome Technologies Inc. a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that it has appointed Dr. Bharatt Chowrira to its Board of Directors. Chowrira has more than 20 years of industry experience that spans progressively senior management positions serving on and working with the boards of private and public companies."/>
Critical Outcome Appoints Dr. Bharatt Chowrira to Its Board of Directors
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, antibiotic, and anti-inflammatory applications, today provided a fiscal year-end business update including a timeline of key upcoming milestones. Leo Ehrlich, Chief Executive Officer, commented, "We are extremely pleased with the tremendous progress that we have made, especially within the last 12 months."/>
Cellceutix Corporation Provides Business Update and Timeline of Upcoming Milestones
Cynosure, Inc. today announced that Stephen J. Webber will join the Company on October 10, 2016 as Executive Vice President. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in November of Cynosure's Quarterly Report on Form 10- Q for the quarter ending September 30, 2016. He will succeed Timothy W. Baker, who in May announced his planned retirement from Cynosure to pursue..."/>
Cynosure to Name Stephen J. Webber as New Chief Financial Officer
Aytu BioScience Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that the September 8 presentation from Chief Executive Officer, Josh Disbrow is now available for on-demand viewing at..."/>
Aytu BioScience Presentation Now Available for On-Demand Viewing
Aytu BioScience Inc., a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that the September 8 presentation from Chief Executive Officer, Josh Disbrow is now available for on-demand viewing at..."/>
Aytu BioScience Presentation Now Available for On-Demand Viewing
EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate, has received the second year of funding of $448,185 from the U.S. Army Medical Research and Materiel Command to continue the development of its proprietary thiolated hyaluronic acid for use as an..."/>
EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today that it expects to launch a Bluetooth ® version of its FDA-cleared Caregiver ® infrared, non-contact thermometer by early 2017. The Bluetooth-enabled Caregiver is designed to connect wirelessly to electronic health record systems and other hospital equipment such as patient monitoring stations.. The new Caregiver Bluetooth-enabled..."/>
PositiveID to Launch Bluetooth Version of its Caregiver Non-Contact Thermometer by Early 2017
Ligand Pharmaceuticals Incorporated announces the initiation of a Phase 2 clinical trial with the Company’ s glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus. This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin. The multiple site study is expected..."/>
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
DelMar Pharmaceuticals, Inc., today announced that the Company and its collaborators from the University of Texas MD Anderson Cancer Center presented new data in a research poster entitled " Activity of dianhydrogalactitol in ovarian tumor models, sensitive or resistant to cisplatin" at the 11 th Biennial Ovarian Cancer Research Symposium. The data, presented on the evening of Monday, September 12 th at the Rivkin Center..."/>
DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium
OPKO Health, Inc. announces the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016.. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories."/>
OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology765 Articles
Consumer Discretionary667 Articles
Financials524 Articles
Health Care433 Articles
Industrials431 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at